問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Yunlin Branch  (在職)

Division of General Internal Medicine

Digestive System Department

National Taiwan University Hospital Yunlin Branch (在職)

Digestive System Department

國立臺灣大學醫學院附設醫院雲林分院

Division of General Internal Medicine

更新時間：2023-09-19

陳健弘Chen, Chien-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳健弘

List

57Cases

2018-01-01 - 2020-12-31

Phase II

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

  • Condition/Disease

    Chronic HBV Infection (Genotype A or B)

  • Test Drug

    ARB-001467 Injection (2 mg/mL)

Participate Sites
6Sites

Terminated4Sites

彭成元
China Medical University Hospital-Taipei

未分科

林俊彥
Linkou Chang Gung Medical Foundation

Digestive System Department

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
11Sites

Terminated11Sites

2011-06-01 - 2014-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
8Sites

Terminated8Sites

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-02-01 - 2017-06-30

Phase II

A MULTIPLE-CENTER, RANDOMIZED, PARTIALLY DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTIVIRAL EFFECTS OF 12-WEEK TREATMENT WITH RO6864018 IN VIROLOGICALLY SUPPRESSED ENTECAVIR TREATED PATIENTS WITH HEPATITIS B VIRUS INFECTION

  • Condition/Disease

    HEPATITIS B VIRUS(HBV) INFECTION

  • Test Drug

    RO6864018

Participate Sites
2Sites

Terminated2Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2018-03-01 - 2021-01-04

Phase II

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

  • Condition/Disease

    Previously Treated Unresectable Hepatocellular Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-08-23 - 2020-07-31

Phase II

A phase II, Multi-Center, Open-Label, Single-Arm Study to evaluate the clinical validity and safety of IOP injection for magnetic resonance imaging (MRI) contrast agent in patients with Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    IOP injection

Participate Sites
8Sites

Not yet recruiting6Sites

Terminated1Sites

2011-06-15 - 2013-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-06-01 - 2011-06-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB